Upifitamab Rilsodotin (UpRi)

UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes Mersana’s Dolaflexin platform to deliver approximately 10 DolaLock payload molecules per antibody. NaPi2b is an antigen that is broadly expressed in ovarian cancer and other cancers. We are investigating UpRi in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer.

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for UpRi for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic therapy or patients who have received four prior lines of systemic therapy regardless of platinum status.


For more information on the UPLIFT study in platinum-resistant ovarian cancer, visit clinicaltrials.gov (NCT03319628).

For more information on the UPGRADE combination study in platinum-sensitive ovarian cancer, visit clinicaltrials.gov (NCT04907968). 

For more information on the UP-NEXT study in recurrent platinum-sensitive ovarian cancer, visit clinicaltrials.gov (NCT05329545).

Expanded Access Policy:

Expanded access, or compassionate use, is the use of an investigational product prior to regulatory approval and outside of a clinical trial. Mersana does not currently have an expanded access program or compassionate use program for any of our investigational products. We understand that for people living with cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trials is the best path to meet our goal of providing new treatments to patients with cancer. We encourage any person with cancer interested in gaining access to our investigational therapies to consult their physician(s) regarding the possibility of participating in one of our clinical trials.